Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-09-10T14:30:34.000Z.
Quote observation: 2026-09-10T14:30:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d670d92a9ed985c4ba88d5830250f1e4eb43691fb1e0723b4e8904464d1c2daf
PE RATIO
N/A
Market Cap
$10.49B
PE Ratio
7.10
TTM Avg
8.78
3Y Avg
12.12
5Y Avg
12.16
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $10.68B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.73B | 26.02 | 29.04 | 38.18 | 44.41 |
| The Cooper Companies, Inc. (COO)vs › | $10.59B | N/A | 43.12 | 49.54 | 34.04 |
| Universal Health Services, Inc. (UHS)vs › | $10.49B | 7.10 | 8.78 | 12.12 | 12.16 |
| Molina Healthcare, Inc. (MOH)vs › | $10.42B | 1050.89 | 158.09 | 64.39 | 48.41 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.10B | 45.50 | 31.77 | 30.82 | 19.03 |
| The Ensign Group, Inc. (ENSG)vs › | $10.07B | 27.09 | 30.99 | 30.47 | 27.64 |
| Bio-Techne Corporation (TECH)vs › | $11.32B | 62.30 | 109.03 | 76.59 | 73.74 |
| Henry Schein, Inc. (HSIC)vs › | $10.02B | 25.64 | 23.68 | 23.83 | 21.79 |
| Globus Medical, Inc. (GMED)vs › | $10.01B | 19.07 | 23.36 | 68.20 | 56.97 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$60.95
Forward EPS (Est.)
$-0.20
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
